Trials / Completed
CompletedNCT03703102
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 274 (actual)
- Sponsor
- Kyowa Kirin, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK4083 | Anti-OX40 Monoclonal Antibody KHK4083 |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2018-10-22
- Primary completion
- 2020-02-06
- Completion
- 2020-11-12
- First posted
- 2018-10-11
- Last updated
- 2024-04-26
- Results posted
- 2022-06-09
Locations
58 sites across 4 countries: United States, Canada, Germany, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03703102. Inclusion in this directory is not an endorsement.